Cortechs.ai

QUANTITATIVE NEUROIMAGING

Objective Imaging Across the Alzheimer's Journey

A connected suite of MRI and advanced PET analysis that turns scans into reproducible, quantitative metrics –supporting confident decisions from first concern to long-term management.

The Alzheimer's Diagnostic Journey

Cortechs.ai tools provide objective, reproducible insight to guide confident decisions at every phase of Alzheimer's disease management – three solutions across four stages spanning one continuum of care.

1

INITIAL CONCERN

NeuroQuant®

Measures brain volume change – e.g. hippocampal atrophy – to support early identification of neurodegeneration and objectively evaluate memory complaints and MCI against a normative database.

2

DIAGNOSTIC WORKUP

NeuroQuant® PET

Quantifies amyloid with standardized Centiloid scaling to support objective amyloid burden – enhancing diagnostic confidence and treatment planning decisions.

3

TREATMENT & MONITORING

NeuroQuant®

Lesion Surveillance

Segments and quantifies FLAIR and T2*GRE/SWI lesions to assist surveillance of lesions for patients on anti-amyloid therapy, with longitudinal change since baseline to monitor lesion changes.

4

ADVANCED MANAGEMENT

NeuroQuant®

Reproducible metrics on atrophy and white matter hyperintensities support care planning, document disease progression, and align multidisciplinary teams on long-term management.

Automated

Fully automated segmentation and quantification – no manual tracing – delivered as DICOM images directly into your workflow.

Longitudinal

Track change vs baseline and prior timepoints to monitor progression and treatment response.


Reproducible

Automated, vendor-agnostic analysis that reduces subjectivity and integrates into PACS workflows.

THE SOLUTIONS

Three tools. One continuum of care.

> *"NeuroQuant® is the clinical gold standard for MRI brain volume measurement."* **— Dr. David E. Ross, MD, Director, Virginia Institute of Neuropsychiatry**




Dementia — Age-Related Atrophy Report

01 NeuroQuant® · Atrophy

Best-in-class automated brain segmentation and volumetric MRI analysis, delivered as a DICOM images directly into your radiology workflow.

- Hippocampal, entorhinal & ventricular volumes vs. age/sex-matched norms
- Hippocampal Occupancy Score (HOC) & normative percentiles
- Dynamic Atlas™ + deep-learning segmentation, ages 3–100
- Quantifies WMH burden with an automated Fazekas score




Amyloid PET Report with Centiloid

02 NeuroQuant® PET · SUVR & Centiloid

Objective quantification of amyloid PET to support clinical assessment and staging – with standardized Centiloid scaling for cross-study and longitudinal consistency.

- Standardized **Centiloid value** on a 0–100 amyloid scale
- Supports Florbetapir, Florbetaben & Flutemetamol tracers
- Composite SUVR guided by the NeuroQuant® Atlas
- Compatible with PET-MR, PET-CT, and PET only workflows



FLAIR & GRE/SWI Surveillance Reports

03 NeuroQuant® Lesion Surveillance · Lesion Tracking

Precise, automated segmentation and longitudinal tracking of treatment-related lesions – built to support amyloid-therapy MRI surveillance while reducing reader subjectivity.

- FLAIR surveillance of **edematous lesions**: new hyperintensity, max diameter & volume change vs. baseline
- Monitors lesion counts & max diameters across baseline and prior timepoints
- GRE/SWI surveillance of **microhemorrhage** and superficial siderosis counts by region
- Comprehensive baseline with FLAIR Fazekas score for context

Cortechs.ai

www.cortechs.ai · +1 858 459 9700

Speak to an account manager: sales@cortechs.ai

NEUROQUANT® PET
FDA CLEARED (amyloid) · Tau & FDG: Research Use Only

Reports shown are illustrative. NeuroQuant® is FDA cleared and CE marked for clinical use. NeuroQuant® PET is FDA cleared for automated regional quantification of amyloid PET; tau and FDG reports and Z-scores are Research Use Only. Refer to product labeling for intended use. NeuroQuant® is a registered trademark of CorTechs Labs, Inc. DBA Cortechs.ai